CN101939004A - 度洛西汀的缓释药物组合物 - Google Patents

度洛西汀的缓释药物组合物 Download PDF

Info

Publication number
CN101939004A
CN101939004A CN2009801017187A CN200980101718A CN101939004A CN 101939004 A CN101939004 A CN 101939004A CN 2009801017187 A CN2009801017187 A CN 2009801017187A CN 200980101718 A CN200980101718 A CN 200980101718A CN 101939004 A CN101939004 A CN 101939004A
Authority
CN
China
Prior art keywords
duloxetine
particle size
composition
pharmaceutically acceptable
enteric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801017187A
Other languages
English (en)
Chinese (zh)
Inventor
布莱特·安东尼·穆尼
帕纳吉奥塔斯·克莱米达斯
菲利普·约翰·费尔库桑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alphapharm Pty Ltd
Original Assignee
Alphapharm Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008900332A external-priority patent/AU2008900332A0/en
Application filed by Alphapharm Pty Ltd filed Critical Alphapharm Pty Ltd
Publication of CN101939004A publication Critical patent/CN101939004A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2009801017187A 2008-01-25 2009-01-09 度洛西汀的缓释药物组合物 Pending CN101939004A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2008900332A AU2008900332A0 (en) 2008-01-25 Delayed Release Composition and Compound
AU2008900332 2008-01-25
PCT/AU2009/000028 WO2009092129A1 (en) 2008-01-25 2009-01-09 Delayed release pharmaceutical composition of duloxetine

Publications (1)

Publication Number Publication Date
CN101939004A true CN101939004A (zh) 2011-01-05

Family

ID=40900727

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801017187A Pending CN101939004A (zh) 2008-01-25 2009-01-09 度洛西汀的缓释药物组合物

Country Status (7)

Country Link
US (1) US20110070299A1 (enExample)
EP (1) EP2240173A4 (enExample)
JP (1) JP2011510024A (enExample)
CN (1) CN101939004A (enExample)
AU (1) AU2009206204B2 (enExample)
CA (1) CA2712282A1 (enExample)
WO (1) WO2009092129A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102908331A (zh) * 2011-08-01 2013-02-06 浙江九洲药物科技有限公司 一种盐酸度洛西汀肠溶胶囊及其制备方法
CN103127023A (zh) * 2013-03-01 2013-06-05 南京正宽医药科技有限公司 一种盐酸度洛西汀肠溶片及其制备方法
CN103393615A (zh) * 2013-07-24 2013-11-20 海南华益泰康药业有限公司 一种度洛西汀肠溶小丸及其制备方法
CN104414993A (zh) * 2013-08-20 2015-03-18 天津药物研究院 一种盐酸度洛西汀肠溶微丸胶囊及其制备方法
CN116617189A (zh) * 2023-07-26 2023-08-22 四川尚锐生物医药有限公司 一种盐酸度洛西汀缓释胶囊及其制备方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663661B2 (en) 2009-12-23 2014-03-04 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN102579403B (zh) * 2011-12-26 2013-08-21 天津市嵩锐医药科技有限公司 盐酸度洛西汀药物组合物
US8313774B1 (en) * 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
GR1008228B (el) * 2013-04-23 2014-06-16 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
JP6815109B2 (ja) * 2016-06-23 2021-01-20 キョーリンリメディオ株式会社 デュロキセチンまたは薬学的に許容されるその塩を有効成分とする医薬組成物
JP6972674B2 (ja) * 2017-06-06 2021-11-24 ニプロ株式会社 経口医薬製剤
JP7046323B2 (ja) * 2017-09-13 2022-04-04 アリメント工業株式会社 多層被覆製剤
JP2020029447A (ja) * 2018-06-25 2020-02-27 大原薬品工業株式会社 腸溶性高分子及び抗付着剤を含有する顆粒
WO2021126098A1 (en) * 2019-12-18 2021-06-24 Santa Farma İlaç Sanayi̇ A.Ş. Gastro-resistant pellet comprising duloxetine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
EP1171417B1 (en) * 1999-04-09 2005-11-09 Eli Lilly And Company Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof
US6420473B1 (en) * 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
WO2003094900A1 (en) * 2002-05-13 2003-11-20 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
EP1565182A1 (en) * 2002-11-19 2005-08-24 Eli Lilly And Company Treatment of gastrointestinal disorders with duloxetine
US7625932B2 (en) * 2003-10-08 2009-12-01 Eli Lilly And Company Pyrrole and pyrazole derivatives as potentiators of glutamate receptors
US20050250838A1 (en) * 2004-05-04 2005-11-10 Challapalli Prasad V Formulation for sustained delivery
CN101132777A (zh) * 2004-12-20 2008-02-27 科利吉姆制药公司 用于睡眠障碍的药物组合物
EP1904039A2 (en) * 2005-06-20 2008-04-02 Cadila Healthcare Ltd. Controlled release dosage formulation of duloxetine
EP1976844A4 (en) 2006-01-06 2010-11-03 Msn Lab Ltd IMPROVED METHOD FOR PURE DULOXETIN HYDROCHLORIDE
EP1820800A1 (en) * 2006-02-17 2007-08-22 KRKA, tovarna zdravil, d.d., Novo mesto Crystalline forms of duloxetine hydrochloride and processes for their preparation
CA2651716A1 (en) * 2006-05-22 2007-12-06 Gershon Kolatkar Duloxetine hydrochloride delayed release formulations
US20110008439A1 (en) * 2006-12-27 2011-01-13 Lek Pharmaceuticals D.D. Duloxetin composition

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102908331A (zh) * 2011-08-01 2013-02-06 浙江九洲药物科技有限公司 一种盐酸度洛西汀肠溶胶囊及其制备方法
CN103127023A (zh) * 2013-03-01 2013-06-05 南京正宽医药科技有限公司 一种盐酸度洛西汀肠溶片及其制备方法
CN103393615A (zh) * 2013-07-24 2013-11-20 海南华益泰康药业有限公司 一种度洛西汀肠溶小丸及其制备方法
CN103393615B (zh) * 2013-07-24 2015-07-15 海南华益泰康药业有限公司 一种度洛西汀肠溶小丸及其制备方法
CN104414993A (zh) * 2013-08-20 2015-03-18 天津药物研究院 一种盐酸度洛西汀肠溶微丸胶囊及其制备方法
CN116617189A (zh) * 2023-07-26 2023-08-22 四川尚锐生物医药有限公司 一种盐酸度洛西汀缓释胶囊及其制备方法
CN116617189B (zh) * 2023-07-26 2023-09-26 四川尚锐生物医药有限公司 一种盐酸度洛西汀缓释胶囊及其制备方法

Also Published As

Publication number Publication date
WO2009092129A8 (en) 2009-10-22
AU2009206204B2 (en) 2015-03-19
US20110070299A1 (en) 2011-03-24
WO2009092129A1 (en) 2009-07-30
JP2011510024A (ja) 2011-03-31
AU2009206204A1 (en) 2009-07-30
EP2240173A4 (en) 2013-07-17
EP2240173A1 (en) 2010-10-20
CA2712282A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
CN101939004A (zh) 度洛西汀的缓释药物组合物
US5985322A (en) Method for the treatment of CNS disorders
NO312397B1 (no) Enteriske duloxetinpellets
US20110052647A1 (en) Antidepressant Oral Pharmaceutical Compositions
AU2017215530B2 (en) Galenic formulations of organic compounds
MX2012007448A (es) Composicion farmaceutica de liberacion controlada.
BRPI0714915A2 (pt) composiÇço farmacÊuticas; formas de dosagem farmacÊutica; e processo para o preparo de uma composiÇço farmacÊutica
CN101808665A (zh) 阿利吉仑和缬沙坦的药物组合
CA2860098A1 (en) Immediate release multi unit pellet system
EP2599477A1 (en) 4-Phenylbutyric acid sustained release formulation
TW200940057A (en) Formulations of flibanserin
US20120003303A1 (en) Oral enteric antidepressant formulation
JP7021108B2 (ja) ニコチンアミドの経口薬学的組成物
CN102908331A (zh) 一种盐酸度洛西汀肠溶胶囊及其制备方法
US8313766B2 (en) Oral antidepressant formulation with reduced excipient load
CN100362997C (zh) 一种度洛西汀肠溶包衣片剂及其制备方法
WO2017093890A1 (en) Clobazam tablet formulation and process for its preparation
CN107441051B (zh) 一种盐酸普罗帕酮微片及其制备方法
CN110420195B (zh) 盐酸度洛西汀肠溶制剂、其主药层及其混悬液、其隔离层及其包衣液、及其制备方法
JP7714473B2 (ja) ピリミジニルアミノピラゾール化合物の調節放出製剤および処置方法
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
CN104490849A (zh) 一种高密度的富马酸二甲酯肠溶颗粒及其制备方法
JP2018016622A (ja) デュロキセチン含有医薬組成物
TWI686195B (zh) 吡咯羧醯胺之固體組成物及其製法
HK40053086A (en) Coating method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110105